104 related articles for article (PubMed ID: 24502538)
21. MiRNAs as biomarkers and therapeutic targets in cancer.
Heneghan HM; Miller N; Kerin MJ
Curr Opin Pharmacol; 2010 Oct; 10(5):543-50. PubMed ID: 20541466
[TBL] [Abstract][Full Text] [Related]
22. The therapeutic potential of microRNAs in cancer.
Thorsen SB; Obad S; Jensen NF; Stenvang J; Kauppinen S
Cancer J; 2012; 18(3):275-84. PubMed ID: 22647365
[TBL] [Abstract][Full Text] [Related]
23. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.
Frau M; Biasi F; Feo F; Pascale RM
Mol Aspects Med; 2010 Apr; 31(2):179-93. PubMed ID: 20176048
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA dysregulation in cancer: opportunities for the development of microRNA-based drugs.
Nana-Sinkam SP; Croce CM
IDrugs; 2010 Dec; 13(12):843-6. PubMed ID: 21154140
[TBL] [Abstract][Full Text] [Related]
25. MicroRNAs as new therapeutic targets and tools in cancer.
Gandellini P; Profumo V; Folini M; Zaffaroni N
Expert Opin Ther Targets; 2011 Mar; 15(3):265-79. PubMed ID: 21208133
[TBL] [Abstract][Full Text] [Related]
26. Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines.
Zhuo L; Liu J; Wang B; Gao M; Huang A
Oncol Rep; 2013 Feb; 29(2):555-62. PubMed ID: 23229111
[TBL] [Abstract][Full Text] [Related]
27. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy.
Cho WC
Int J Biochem Cell Biol; 2010 Aug; 42(8):1273-81. PubMed ID: 20026422
[TBL] [Abstract][Full Text] [Related]
28. MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells.
Yang T; Zheng ZM; Li XN; Li ZF; Wang Y; Geng YF; Bai L; Zhang XB
Exp Biol Med (Maywood); 2013 Sep; 238(9):1024-32. PubMed ID: 23925649
[TBL] [Abstract][Full Text] [Related]
29. Implication of miRNA in the diagnosis and treatment of breast cancer.
Castañeda CA; Agullo-Ortuño MT; Fresno Vara JA; Cortes-Funes H; Gomez HL; Ciruelos E
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1265-75. PubMed ID: 21916580
[TBL] [Abstract][Full Text] [Related]
30. Molecular mechanisms and theranostic potential of miRNAs in drug resistance of gastric cancer.
Yang W; Ma J; Zhou W; Cao B; Zhou X; Yang Z; Zhang H; Zhao Q; Fan D; Hong L
Expert Opin Ther Targets; 2017 Nov; 21(11):1063-1075. PubMed ID: 28994330
[TBL] [Abstract][Full Text] [Related]
31. MicroRNAs: novel mediators of resistance to microtubule-targeting agents.
Kanakkanthara A; Miller JH
Cancer Treat Rev; 2013 Apr; 39(2):161-70. PubMed ID: 22902296
[TBL] [Abstract][Full Text] [Related]
32. MicroRNAs in breast cancer pathogenesis.
Götte M
Minerva Ginecol; 2010 Dec; 62(6):559-71. PubMed ID: 21079577
[TBL] [Abstract][Full Text] [Related]
33. MicroRNAs horizon in retinoblastoma.
Mirakholi M; Mahmoudi T; Heidari M
Acta Med Iran; 2013; 51(12):823-9. PubMed ID: 24442535
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.
Giovannetti E; Erozenci A; Smit J; Danesi R; Peters GJ
Crit Rev Oncol Hematol; 2012 Feb; 81(2):103-22. PubMed ID: 21546262
[TBL] [Abstract][Full Text] [Related]
35. Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis.
Koturbash I; Zemp FJ; Pogribny I; Kovalchuk O
Mutat Res; 2011 Jun; 722(2):94-105. PubMed ID: 20472093
[TBL] [Abstract][Full Text] [Related]
36. Targeting microRNAs to modulate TRAIL-induced apoptosis of cancer cells.
Lu T; Shao N; Ji C
Cancer Gene Ther; 2013 Jan; 20(1):33-7. PubMed ID: 23138871
[TBL] [Abstract][Full Text] [Related]
37. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma.
Montero J; Morales A; Llacuna L; Lluis JM; Terrones O; Basañez G; Antonsson B; Prieto J; García-Ruiz C; Colell A; Fernández-Checa JC
Cancer Res; 2008 Jul; 68(13):5246-56. PubMed ID: 18593925
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy.
Ko MA; Zehong G; Virtanen C; Guindi M; Waddell TK; Keshavjee S; Darling GE
Ann Thorac Surg; 2012 Oct; 94(4):1094-102; discussion 1102-3. PubMed ID: 22939244
[TBL] [Abstract][Full Text] [Related]
39. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy.
Drebber U; Lay M; Wedemeyer I; Vallböhmer D; Bollschweiler E; Brabender J; Mönig SP; Hölscher AH; Dienes HP; Odenthal M
Int J Oncol; 2011 Aug; 39(2):409-15. PubMed ID: 21567082
[TBL] [Abstract][Full Text] [Related]
40. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
Zhu W; Xu H; Zhu D; Zhi H; Wang T; Wang J; Jiang B; Shu Y; Liu P
Cancer Chemother Pharmacol; 2012 Mar; 69(3):723-31. PubMed ID: 21993663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
